ClearBridge Investments’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $39.7M | Sell |
63,636
-10,156
| -14% | -$6.91M | 0.03% | 364 |
|
|
2026
Q1 | $57M | Buy |
73,792
+11,761
| +19% | +$9M | 0.05% | 288 |
|
|
2025
Q4 | $47.9M | Sell |
62,031
-2,695
| -4% | -$1.83M | 0.04% | 329 |
|
|
2025
Q3 | $36.4M | Buy |
64,726
+52,881
| +446% | +$29.9M | 0.03% | 370 |
|
|
2025
Q2 | $6.22M | Buy |
11,845
+5,121
| +76% | +$2.86M | 0.01% | 547 |
|
|
2025
Q1 | $4.26M | Buy |
6,724
+2,746
| +69% | +$1.89M | ﹤0.01% | 578 |
|
|
2024
Q4 | $2.83M | Buy |
3,978
+26
| +0.7% | +$21.8K | ﹤0.01% | 608 |
|
|
2024
Q3 | $4.15M | Buy |
3,952
+2,519
| +176% | +$2.8M | ﹤0.01% | 589 |
|
|
2024
Q2 | $1.51M | Buy |
+1,433
| New | +$1.39M | ﹤0.01% | 644 |
|
|
2020
Q3 | – | Sell |
-80
| Closed | -$50K | – | 941 |
|
|
2020
Q2 | $50K | Buy |
+80
| New | +$45.4K | ﹤0.01% | 789 |
|
|
2019
Q2 | – | Sell |
-118,775
| Closed | -$48.8M | – | 1118 |
|
|
2019
Q1 | $48.8M | Sell |
118,775
-759,190
| -86% | -$313M | 0.04% | 312 |
|
|
2018
Q4 | $328M | Buy |
877,965
+6,274
| +0.7% | +$2.3M | 0.33% | 86 |
|
|
2018
Q3 | $352M | Sell |
871,691
-4,638
| -0.5% | -$1.77M | 0.3% | 101 |
|
|
2018
Q2 | $302M | Buy |
876,329
+36,177
| +4% | +$11.3M | 0.25% | 118 |
|
|
2018
Q1 | $289M | Buy |
840,152
+33,390
| +4% | +$11.6M | 0.27% | 109 |
|
|
2017
Q4 | $303M | Buy |
806,762
+47,010
| +6% | +$19M | 0.28% | 109 |
|
|
2017
Q3 | $340M | Buy |
759,752
+29,181
| +4% | +$13.9M | 0.33% | 93 |
|
|
2017
Q2 | $359M | Buy |
730,571
+40,317
| +6% | +$17.6M | 0.35% | 86 |
|
|
2017
Q1 | $267M | Buy |
690,254
+245,531
| +55% | +$91M | 0.27% | 110 |
|
|
2016
Q4 | $163M | Buy |
444,723
+116,480
| +35% | +$44.3M | 0.18% | 140 |
|
|
2016
Q3 | $132M | Buy |
328,243
+26,151
| +9% | +$10.5M | 0.15% | 148 |
|
|
2016
Q2 | $106M | Buy |
302,092
+21,667
| +8% | +$8.34M | 0.12% | 165 |
|
|
2016
Q1 | $101M | Buy |
280,425
+96,330
| +52% | +$39.7M | 0.12% | 166 |
|
|
2015
Q4 | $99.9M | Buy |
184,095
+7,859
| +4% | +$4.26M | 0.12% | 175 |
|
|
2015
Q3 | $82M | Sell |
176,236
-18,505
| -10% | -$9.94M | 0.1% | 197 |
|
|
2015
Q2 | $99.3M | Buy |
194,741
+12,161
| +7% | +$5.93M | 0.11% | 191 |
|
|
2015
Q1 | $82.4M | Buy |
182,580
+2,990
| +2% | +$1.27M | 0.09% | 217 |
|
|
2014
Q4 | $73.7M | Sell |
179,590
-978
| -0.5% | -$385K | 0.08% | 227 |
|
|
2014
Q3 | $65.1M | Buy |
180,568
+137,837
| +323% | +$46.2M | 0.07% | 244 |
|
|
2014
Q2 | $12.1M | Buy |
42,731
+39,939
| +1,430% | +$11.8M | 0.01% | 497 |
|
|
2014
Q1 | $838K | Sell |
2,792
-254
| -8% | -$78.3K | ﹤0.01% | 742 |
|
|
2013
Q4 | $838K | Buy |
3,046
+635
| +26% | +$183K | ﹤0.01% | 723 |
|
|
2013
Q3 | $754K | Sell |
2,411
-602
| -20% | -$158K | ﹤0.01% | 719 |
|
|
2013
Q2 | $678K | Buy |
+3,013
| New | +$702K | ﹤0.01% | 715 |
|
Other funds holding REGN
ClearBridge Investments's REGN Position: Q2 2026 in Review
ClearBridge Investments reduced its Regeneron Pharmaceuticals (REGN) stake by 14% in Q2 2026, selling an estimated $6.91M and leaving 63,636 shares worth $39.7M. The position accounts for 0.03% of the portfolio, ranked #364.
ClearBridge Investments first reported a position in REGN in Q2 2013 and has held it in 34 quarters since. The position peaked at $359M in Q2 2017. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- ClearBridge Investments held 63,636 shares of Regeneron Pharmaceuticals worth $39.7M as of Q2 2026.
- ClearBridge Investments sold 10,156 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $6.91M.
- Regeneron Pharmaceuticals made up 0.03% of ClearBridge Investments's portfolio in Q2 2026, its #364 holding.
- ClearBridge Investments first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 34 quarters since.
- ClearBridge Investments's Regeneron Pharmaceuticals position peaked at $359M in Q2 2017.
- 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on ClearBridge Investments's 13F filing for Q2 2026, filed 13 Aug 2026.